Salute e Benessere

Growth Hormone Deficiency Market Poised to Reach US$ 7 Billion by 2034, Driven…

A notable trend is the increasing focus on digital health solutions. Telemedicine and digital platforms are facilitating remote patient monitoring, enhancing treatment adherence, and improving overall patient outcomes. These technologies are particularly beneficial in regions with limited healthcare access, thereby expanding the reach of growth hormone deficiency therapies. A notable trend is the increasing focus on digital health solutions. Telemedicine and digital platforms are facilitating...
PR Newswire
18/07/2024

Active Pharmaceutical Ingredients CDMO Market to be dominated by Oncology…

The Active Pharmaceutical Ingredients CDMO Market research provides in-depth details on important variables such as motivating factors and obstacles that are expected to determine the market's future growth. Along with a thorough analysis of the competitive landscape, the report also includes available opportunities for stakeholders to invest in the Active Pharmaceutical Ingredients CDMO Market. Both qualitative and quantitative characteristics of the industry have also been covered in the…
PR Newswire
18/07/2024

Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024

Houston, Texas and Tuebingen, Germany, July 18, 2024–Immatics N.V.(NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-concept clinical data for its next-generation, half-life extended TCR Bispecific molecule, TCER® IMA401 (MAGEA4/8), will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024...
Nasdaq GlobeNewswire
18/07/2024

Novo Holdings Portfolio Company Invetx to be Acquired by Dechra Pharmaceuticals

Novo Holdings co-led Invetx's Series B financing round in 2022, which enabled Invetx to advance its mAb pipeline and pursue market approvals for therapeutics targeting chronic and serious diseases in dogs and cats. This investment reflects Novo Holdings' strong track record of investing in and nurturing the development of innovative life sciences companies that are at the forefront of the development of cutting-edge solutions. Invetx was incubated by Anterra Capital, a Boston and Amsterdam based…
PR Newswire
18/07/2024

New data for Roche's Susvimo demonstrates sustained efficacy in two serious…

Two-year Phase III data presented at ASRS 2024 show Susvimo's potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR)Safety data were consistent with the known safety profile for Susvimo in people with DME and DRAdditionally, the US FDA has accepted the filing application for Susvimo in DME and DR based on one-year Pagoda and Pavilion study dataSusvimo is a unique therapeutic approach that provides continuous delivery of...
Nasdaq GlobeNewswire
18/07/2024

Haier Smart Home Intends to Acquire Electrolux South Africa's Water Heater…

The acquisition is an important step in the strategic implementation of Haier Smart Home's development in African market. The acquisition is an important step in the strategic implementation of Haier Smart Home's development in African market. Leveraging Kwikot's extensive HVAC channel and service coverage, Haier Smart Home will realize synergies in product and supply chain management to expand Kwikot's water heater lineups and unlock potentials in solar water heaters and water purifiers...
PR Newswire
18/07/2024

Cast Saw Devices Market to be worth US$ 273.6 Million by 2031 | States…

Cast saw devices are specialized tools used for safely and effectively removing orthopedic casts. These devices typically feature oscillating blades designed to cut through hard materials like plaster or fiberglass without harming the underlying skin. The global increase in orthopedic conditions, such as arthritis, degenerative disorders, and fractures, is a key factor augmenting the cast saw devices market growth. These conditions make casts and medical casting saw devices critical care…
PR Newswire
18/07/2024

Anal Irrigation System Market to Reach USD 443.6 Million by 2031, Driven by…

With the rapidly changing lifestyles, people have been inclined more toward the consumption of alcohol and smoking. Such lifestyle habits are propelling the cases of cancer worldwide. Owing to a lack of eating habits, excessive alcohol consumption, smoking, and many more factors, the prevalence of colorectal cancer is expected to increase during the forecast period. With the rapidly changing lifestyles, people have been inclined more toward the consumption of alcohol and smoking. Such...
PR Newswire
18/07/2024

Foreign Affairs Minister Mélanie Joly announces Canada's intention to join…

George Bickerstaff, Chairperson of IVI's BOT, said: "On behalf of the BOT, it is my great pleasure to share that the Board has approved Canada's request to join IVI as a State Party. We look to our member countries for guidance on how best to serve the international community and deliver on not only IVI's goals but their contributions to the Sustainable Development Goals as well. With Canada's membership, IVI and its Global Council will gain a critical new voice to champion equitable global…
PR Newswire
18/07/2024

Brainomix and Boehringer Ingelheim Launch Strategic Partnership in Fibrosing…

Pulmonary fibrosis is a chronic lung condition that is progressive and life-limiting. Untreated, patients can have a lifespan as short as 5 years from diagnosis, and yet despite this, often wait up to 2 years for diagnosis. The key to the best survival for patients with fibrosing lung disease is the earliest initiation of treatment, but identifying patients eligible for treatment based on imaging can be challenging, even for experts. Pulmonary fibrosis is a chronic lung condition that is...
PR Newswire
18/07/2024

Diamyd Medical receives second U.S. FDA Fast Track designation for Diamyd® - for…

For further information regarding Fast Track drug development programs, please refer to the Guidance for Industry: Expedited Programs for Serious Conditions - Drugs and Biologics at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf For further information regarding Fast Track drug development programs, please refer to the Guidance for Industry: Expedited Programs for Serious Conditions - Drugs and Biologics at...
PR Newswire
18/07/2024

Interim report Q2/2024: Enzymatica builds momentum for expansion

"Many factors now point to a favorable pathway for Enzymatica. We are making great strides in research, we have received the MDR certification, we are garnering international interest and we are seeing signs of regulatory developments that could be beneficial to us. At the same time, we need to expand our partner network, which does not happen overnight. Registrations in new countries will delay the launch in the largest international markets and we want to increase our research efforts…
PR Newswire
18/07/2024

Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its…

EMA will now initiate its centralized review procedure under accelerated assessment for Bavarian Nordic's chikungunya vaccineCOPENHAGEN, Denmark, July 18, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA), which was submitted in June 2024 for CHIKV VLP, the Company's vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of...
Nasdaq GlobeNewswire
18/07/2024

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches…

Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncologyFurther data read-outs expected in 2024 in oncology, mental health, and pulmonary fibrosisStrong first half net sales growth of 7.4%* year on year Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported on Thursday significant progress in its pipeline across key therapeutic areas as it reached major milestones in the first half of the year.“We are stepping up our investments in...
Nasdaq GlobeNewswire
18/07/2024

BioWorld by Clarivate Celebrates Nine Wins at 2024 APEX Awards

The APEX Awards, now in their 36th year, recognize outstanding work by professional communicators in areas such as graphic design, editorial content, and overall communications excellence. With over 1,100 entries this year, the competition was fierce, making these nine wins a testament to the continued leadership and innovation in the field by BioWorld. The APEX Awards, now in their 36th year, recognize outstanding work by professional communicators in areas such as graphic design, editorial...
PR Newswire
18/07/2024

Implantica launches RefluxStop™ advanced education program in Spain

Dr. Juan Carlos Ruiz de Adana at Hospital Universitario de Getafe, says, "It's been an immense pleasure to participate in such engaging discussions with other RefluxStopTM users and thought leaders in Spain and other parts of Europe. As an anti-reflux expert, I am excited to see a new technology that has significant potential to improve patient outcomes, demonstrated in my team's first-hand experience using the RefluxStop device over the past year. Such ongoing training and exchanging ideas…
PR Newswire
18/07/2024

Inventiva announces a €20.1 million issuance of royalty certificates

Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng).Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United Kingdom over a 14-year term.Cash runway extended through September 2024 and evaluation of strategic and financing options pursued 1.Daix (France), Long Island City (New York, United States), July 18, 2024– Inventiva (Euronext Paris and Nasdaq:...
Nasdaq GlobeNewswire
18/07/2024

NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment…

Published in NEJM, the pivotal XTEND-Kids study shows ALTUVOCT met primary and key secondary endpoints, which included occurrence of factor VIII inhibitors and annualised bleed rates (ABRs). Results revealed no development of factor VIII inhibitors and sustained protection from bleeding events with once-weekly dosing. These findings support the value of sustaining high factor levels with ALTUVOCT in children with haemophilia A. Published inNEJM, the pivotal XTEND-Kids study shows...
PR Newswire
18/07/2024

Notice of Extraordinary General Meeting in Enzymatica AB (publ)

Those who wish to participate in the annual general meeting must: Those who wish to participate in the annual general meeting must: The notice shall include full name, personal identification number or corporate registration number, address and daytime telephone number and, where appropriate, information about representative, proxy and assistants. The number of assistants may not be more than two (2). The notification should, where appropriate, be accompanied by proxies, registration...
PR Newswire
18/07/2024

Enzymatica's Board of Directors decides on a new rights issue of approximately…

Background and reasonsFor the past three years, Enzymatica's management and board have conducted structured and planned work to prepare the Company for rapid international expansion. The production capacity in the own facility in Iceland has quadrupled and major investments have been made to strengthen the regulatory and scientific documentation about the Company's patented barrier technology and the product ColdZyme. After several important advances in the first half of 2024, Enzymatica is…
PR Newswire
18/07/2024

Pharming Group to report second quarter and first half 2024 financial results on…

Leiden, the Netherlands, July 18, 2024:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on August 1, 2024. To participate in the conference call, please register in advance using the link below. Once registered,...
Nasdaq GlobeNewswire
18/07/2024

Save the date: Essity's Capital Markets Day, December 3, 2024

The day is scheduled to start around 08:00 CET and continue until around 17:00 CET. The day is scheduled to start around08:00 CETand continue until around17:00 CET. The Capital Markets Day is an opportunity for institutional investors, financial analysts and the media to receive an update on Essity's strategy and progress. More information about the event and registration will be provided shortly. The Capital Markets Day is not foreseen to be streamed live, but recorded...
PR Newswire
18/07/2024

Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business…

Financial Performance Financial Performance The Company delivered strong financial performance for the third consecutive quarter with total revenue of 54.2 MSEK. Of this, 47.1 MSEK is attributed to IDEFIRIX sales. This excludes the impact of an approximate 20 MSEK provision related to potential price adjustments from cumulative sales since the launch of IDEFIRIX inEuropein 2020. After accounting for this provision, total IDEFIRIX product sales were 27.2 MSEK. Sales performance was...
PR Newswire
18/07/2024

Nicox Provides Second Quarter 2024 Update

Press ReleaseNicox Provides Second Quarter 2024 Update Nicox Group revenue of €1.6 million (net revenue 1€1.0 million) for second quarter 2024Nicox Group cash of €7.8 million on 30 June 2024 which finances the Company until at least February 2025July 18 th, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the revenue and cash position...
Nasdaq GlobeNewswire
18/07/2024
Altri  Comunicati